Docetaxel and niclosamide-loaded nanofiber systems for improved chemo-therapeutic activity and resistance reversal in prostate cancer

Drug Development and Industrial Pharmacy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 12

Published: Jan. 16, 2025

The objective of the study was to tackle recurrence prostate cancer (PCa) post-surgery and re-sensitize docetaxel (DTX)-resistant PC-3 cells chemo-therapy using NIC. Prolonged DTX therapy leads emergence chemo-resistance by overexpression PI3K-AKT pathway in PCa along with tumor post-surgery. Suppression this could be essential improving anticancer activity re-sensitizing resistant cells. Niclosamide (NIC), an anthelmintic drug has shown tremendous potential re-sensitized various drugs. To mitigate post-surgical recurrence, implant-based system facilitating sustained release NIC beneficial. were incorporated within a nanofiber (NF) prevent on-site local DTX-resistant fabricated DTX-NIC NF via electrospinning 334 ± 96.14 nm diameter demonstrated profile till 6 d. Elevated mitochondrial damage, reactive oxygen species levels apoptotic index revealed improvement cytotoxicity post incorporation into owing their profile. Re-sensitization PC-3/DTX observed introduction which due suppression p-Akt1, overexpressed From superior re-sensitization cells, we conclude that beneficial therapeutic regimen preventing PCa.

Language: Английский

---

QbD Manoeuvred Niclosamide Laden Polylactic-co-Glycolic Acid Nanoparticles-Impregnated Gelatin Nanofibers for the Management of Oral Carcinoma

BioNanoScience, Journal Year: 2025, Volume and Issue: 15(2)

Published: Feb. 5, 2025

Language: Английский

---

Formulation, Optimization, and Evaluation of Lornoxicam-Loaded Novasomes for Targeted Ulcerative Colitis Therapy: In Vitro and In Vivo Investigations

Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 21

Published: Jan. 20, 2025

The purpose of this work was to create and assess Lornoxicam (LOR) loaded Novasomes (Novas) for the efficient treatment ulcerative colitis. study performed using a 23 factorial design investigate impact several formulation variables. Three separate parameters were investigated: Surface Active agent (SAA) type (X1), LOR concentration (X2), SAA: Oleic acid ratio (X3). dependent responses included encapsulation efficiency (Y1: EE %), particle size (Y2: PS), zeta potential (Y3: ZP), polydispersity index (Y4: PDI). vesicles demonstrated remarkable efficiency, ranging from 81.32 ± 3.24 98.64 0.99%. vesicle sizes ranged 329 9.88 583.4 9.04 nm with high negative values. release pattern Novas' biphasic adhered Higuchi's model. An in-vivo assessed how LOR-Novas affected rats' acetic acid-induced colitis (UC). optimized effectively reduced colonic ulceration (P < 0.05) inflammatory pathway via inhibiting Toll-like receptor 4 (TLR4), Nuclear factor kappa β (NF-κβ) inducible nitric oxide (iNO). At same time, it elevated Silent information regulator-1(SIRT-1) glutathione (GSH) colon contents. Thus, current suggested that LOR- Novas may be viable

Language: Английский

---

Dual-ligand functionalized liposomes with iRGD/trastuzumab co-loaded with gefitinib and lycorine for enhanced metastatic breast cancer therapy

Journal of Liposome Research, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 15

Published: Feb. 2, 2025

Personalized treatment strategies have greatly improved the efficacy of anticancer drugs. Nanocarriers, especially liposomes, function as excellent platform for delivery both hydrophilic and hydrophobic agents. iRGD is a peptide composed 9-amino acid denoted (iRGDP), enhances selective intratumoral Trastuzumab (TMAB), mainly targets HER2-positive advanced stage breast cancer an FDA-approved monoclonal antibody. Gefitinib (GEB) drug, effective against metastatic (MBC), while Lycorine hydrochloride (LCOH), naturally derived compound, possess anti-inflammatory properties. This research emphasizing on preparation GEB LCOH-entrapped TPGS-COOH coated-liposomes, camouflaged with antibody (TMAB) cyclic (iRGDP) targeted in MBC therapy. The developed multifunctional liposomes were studied extensive vitro cell line studies MCF-7 cells. half-maximum inhibitory concentration (IC-50) values LCOH co-loaded single functionalized liposome (SFL) (iRGDP-LiP, TMAB-LiP) dual-functionalized (DFL) (iRGDP-TMAB-LiP) cells 1.04 ± 0.023 μg/mL, 0.71 0.018 0.56 0.028 respectively. Inverted confocal laser scanning microscopy (ICLSM) revealed enhanced cellular internalization SFL DFL-treated groups tagged coumarin-6 rhodamine-B dye compared to conventional liposome. scratch assay marked reduction migration, DAPI staining confirmed nuclear condensation (NC) fragmentation (NF) groups. Moreover, flow cytometry demonstrated early late apoptosis DFL These findings indicate that holds promise multifaceted therapeutic approach

Language: Английский

---

Liposome-integrated hydrogel hybrids: Promising platforms for cancer therapy and tissue regeneration

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 368, P. 703 - 727

Published: March 19, 2024

Drug delivery platforms have gracefully emerged as an indispensable component of novel cancer chemotherapy, bestowing targeted drug distribution, elevating therapeutic effects, and reducing the burden unwanted side effects. In this context, hybrid systems artfully harnessing virtues liposomes hydrogels bring remarkable benefits, especially for localized therapy, including intensified stability, excellent amenability to hydrophobic hydrophilic medications, controlled liberation behavior, appropriate mucoadhesion mucopenetration shift. Moreover, three-dimensional biocompatible liposome-integrated hydrogel networks attracted unprecedented interest in tissue regeneration, given their tunable architecture physicochemical properties, well enhanced mechanical support. This review elucidates presents cutting-edge developments recruiting treatment regeneration.

Language: Английский

---

Quality by design endorsed fabrication of Ibrutinib-loaded human serum albumin nanoparticles for the management of leukemia

European Journal of Pharmaceutics and Biopharmaceutics, Journal Year: 2023, Volume and Issue: 190, P. 94 - 106

Published: July 18, 2023

Language: Английский

---

Exploration of Multi-layered Nanofiber Adjuvant Implants of Doxorubicin and Resveratrol to Prevent Post-Surgery Tumor Recurrence and Invasion

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 99, P. 105977 - 105977

Published: July 14, 2024

Language: Английский

---

Raloxifene loaded d-α-tocopherol polyethylene glycol 1000 succinate stabilized poly (ε-caprolactone) nanoparticles augmented drug delivery and apoptosis in breast cancer cells

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 92, P. 105399 - 105399

Published: Jan. 21, 2024

Language: Английский

---

Nanoparticle-enhanced delivery of resveratrol for targeted therapy of glioblastoma: Modulating the Akt/GSK-3β/NF-kB pathway in C6 glioma cells

Brain Research, Journal Year: 2024, Volume and Issue: unknown, P. 149411 - 149411

Published: Dec. 1, 2024

Language: Английский

---

Quality by design fostered fabrication of cabazitaxel loaded pH-responsive Improved nanotherapeutics against prostate cancer

Colloids and Surfaces B Biointerfaces, Journal Year: 2023, Volume and Issue: 234, P. 113732 - 113732

Published: Dec. 27, 2023

Language: Английский

---